Thank you for your interest in RoosterBio's webinar!

Human Mesenchymal Stem/Stromal Cells (hMSCs) are a critical raw material across the Regenerative Medicine space, including extracellular vesicle (EV) and exosome-based therapies. RoosterBio has radically simplified EV-based therapeutic product development from early research and discovery, product and process development, and cGMP manufacturing for clinical implementation or eventual commercialization. Built upon our standardized, high-volume hMSCs, Bioprocess Media Solutions, and low-particulate RoosterCollect EV collection medium and engineered for fed-batch bioreactor scale-up for direct implementation in large scale bioreactor-based EV production and cGMP EV clinical manufacturing.

RoosterBio’s EV Production System builds-in consistency in critical cellular raw materials and enables fold-change improvement in hMSC-EV lot sizes, productivity, and cost-of-goods – industrializing the cGMP EV supply chain. Watch Jon's talk below to learn more!

 

Speaker: Jon Rowley, PhD

Jon A. Rowley, PhD, is the Founder & Chief Product Officer of RoosterBio Inc.  Jon started RoosterBio in 2013 as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices.  Jon holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 35 peer reviewed manuscripts and 20 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy.  Jon started his industry career at BD as a scientist and R&D manager in a Cell & Tissue Technologies group focused on applying high throughput screening technologies to cell therapy media development and tissue engineering.  Jon then contributed to the clinical development of Aastrom Biosciences’ Tissue Repair Cell product, where he was Sr Manager of Process Development responsible for manufacturing process improvements and cell delivery to the patient.  Jon also spent 5 years as Director of Innovation and Process Development in Lonza’s Cell Therapy CMO business, and currently resides in Walkersville, MD with his wonderful wife and their 3 awesome children.

 

About RoosterBio Inc.

RoosterBio, Inc. is a privately held cell manufacturing platform company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. Our products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. We have simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization to the field, accelerating the road to discovery in Regenerative Medicine.

For more information on RoosterBio, please visit http://www.roosterbio.com .